SEC Form 4 · accession 0001179110-16-016967
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Helen Torley
Officer — President and CEO · Director
Period of report
Dec 31, 2015
Accepted (ET)
Jan 4, 2016 · 8:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 31, 2015 | A | 31,500 | $0.00 | A | 99,581 | D | |
| Common StockF2 | Dec 31, 2015 | F | 16,436 | $17.33 | D | 83,145 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents the vesting of performance-based restricted stock units based upon the achievement of certain PEGPH20 clinical program goals.
- F2The reported disposition of 16,436 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding requirements.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney